Table 2.
Current clinical trials of histone modification inhibitors combined with immunotherapy agents.
| Identifier | Recruitment Status | Phase | Cancer Type | Immune Checkpoint Inhibitors | Epigenetic Drugs |
|---|---|---|---|---|---|
| NCT02437136 | Recruiting | I/II | NSCLC and melanoma | Pembrolizumab | Entinostat |
| NCT03179930 | Recruiting | II | Lymphoma Relapsed Refractory | Pembrolizumab | Entinostat |
| NCT02909452 | Active, not recruiting | I | Advanced solid tumors | Pembrolizumab | Entinostat |
| NCT02395627 | Recruiting | II | Breast Neoplasms | Pembrolizumab | Vorinostat |
| NCT02619253 | Recruiting | I | Renal Cell Carcinoma, Urinary Bladder Neoplasms | Pembrolizumab | Vorinostat |
| NCT02538510 | Active, not recruiting | I/II | Recurrent unresectable/metastatic HNSCC and SGC | Pembrolizumab | Vorinostat |
| NCT02512172 | Recruiting | I | Colorectal Cancer | Pembrolizumab | Romidepsin with or without azacytidine(DNMTi) |
| NCT02697630 | Recruiting | II | Metastatic Uveal Melanoma | Pembrolizumab | Entinostat |
| NCT02453620 | Recruiting | I | Breast Adenocarcinoma HER2/Neu Negative Invasive Breast Carcinoma | Ipilimumab | Entinostat |
| NCT03552380 | Recruiting | II | Renal Cell Carcinoma | Pembrolizumab plus Ipilimumab | Entinostat |
| NCT03250273 | Recruiting | II | Cholangiocarcinoma and Pancreatic Cancer and Metastatic Pancreatic Cancer | Nivolumab | Entinostat |
| NCT03278782 | Recruiting | I/II | Lymphoid Haematopoietic Malignant Neoplasms Cutaneous T-Cell Lymphoma Refractory Cutaneous T-cell Lymphoma | Pembrolizumab | Romidepsin |
| NCT03150329 | Recruiting | I | Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma | Pembrolizumab | Vorinostat |
| NCT02915523 | Active, not recruiting | I/II | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | Avelumab | Entinostat |
| NCT02708680 | Recruiting | I/II | Breast Cancer | Atezolizumab | Entinostat |
| NCT02638090 | Recruiting | I/II | Lung Cancer, Non-small Cell Lung Cancer | Pembrolizumab | Vorinostat |
| NCT02220842 | Active, not recruiting | I | Lymphoma | Atezolizumab administered with Obinutuzumab | Tazemetostat |
| NCT03525795 | Recruiting | I/II | Advanced Solid Tumors | Ipilimumab | CPI-1205 |
| NCT02032810 | Active, not recruiting | I | Melanoma/Skin Cancer | Ipilimumab | Panobinostat |